Trexquant Investment LP Purchases 125,604 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC)

Trexquant Investment LP raised its position in Bicycle Therapeutics plc (NASDAQ:BCYC) by 177.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 196,323 shares of the company’s stock after acquiring an additional 125,604 shares during the period. Trexquant Investment LP owned about 0.65% of Bicycle Therapeutics worth $3,550,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Deutsche Bank AG raised its stake in shares of Bicycle Therapeutics by 1,051.4% in the third quarter. Deutsche Bank AG now owns 96,370 shares of the company’s stock valued at $1,936,000 after purchasing an additional 88,000 shares in the last quarter. Braidwell LP bought a new position in shares of Bicycle Therapeutics during the 3rd quarter worth about $25,914,000. Exchange Traded Concepts LLC lifted its holdings in shares of Bicycle Therapeutics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 6,727 shares of the company’s stock worth $122,000 after acquiring an additional 1,706 shares during the period. Polar Capital Holdings Plc increased its stake in Bicycle Therapeutics by 33.2% in the third quarter. Polar Capital Holdings Plc now owns 1,011,500 shares of the company’s stock valued at $20,321,000 after acquiring an additional 252,000 shares during the period. Finally, Jump Financial LLC raised its position in Bicycle Therapeutics by 108.6% in the fourth quarter. Jump Financial LLC now owns 77,332 shares of the company’s stock worth $1,398,000 after purchasing an additional 40,265 shares in the last quarter. Institutional investors own 86.15% of the company’s stock.

Wall Street Analysts Forecast Growth

BCYC has been the topic of several analyst reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $60.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, February 21st. HC Wainwright reiterated a “buy” rating and set a $55.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, May 3rd. Finally, Needham & Company LLC reissued a “buy” rating and set a $43.00 price objective on shares of Bicycle Therapeutics in a report on Wednesday, April 10th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $46.86.

Insiders Place Their Bets

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,158 shares of the business’s stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $23.81, for a total value of $75,191.98. Following the completion of the transaction, the chief executive officer now directly owns 387,270 shares of the company’s stock, valued at $9,220,898.70. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold a total of 5,312 shares of company stock valued at $126,139 in the last 90 days. 8.50% of the stock is currently owned by insiders.

Bicycle Therapeutics Price Performance

NASDAQ BCYC opened at $23.48 on Friday. The stock’s 50 day simple moving average is $23.32 and its 200 day simple moving average is $20.11. Bicycle Therapeutics plc has a one year low of $12.54 and a one year high of $28.91. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.42 and a current ratio of 10.42.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its earnings results on Thursday, May 2nd. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($1.25) by $0.63. Bicycle Therapeutics had a negative return on equity of 49.35% and a negative net margin of 404.14%. The company had revenue of $19.53 million for the quarter, compared to analysts’ expectations of $6.06 million. The company’s revenue was up 298.9% compared to the same quarter last year. Sell-side analysts anticipate that Bicycle Therapeutics plc will post -4.44 EPS for the current fiscal year.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.